Synergistic Reduction Of Listeria Monocytogenes Cold Growth By Lactate And Diacetate by Stasiewicz, Matthew
 SYNERGISTIC REDUCTION OF LISTERIA MONOCYTOGENES COLD 
GROWTH BY LACTATE AND DIACETATE 
 
 
 
 
 
A Thesis 
Presented to the Faculty of the Graduate School 
of Cornell University 
In Partial Fulfillment of the Requirements for the Degree of 
Master of Science 
 
 
 
 
 
 
by 
Matthew Stasiewicz 
January 2011 
 © 2011 Matthew Stasiewicz 
 ABSTRACT 
Listeria monocytogenes is a psychrotolerant foodborne pathogen that is of particular 
concern to the ready-to-eat meat and seafood industries because it‟s ability to grow at 
low temperatures reduces the ability of refrigeration to control the pathogen‟s growth 
in foods.  Because L. monocytogenes generally contaminates foods at low levels and 
has a high infectious dose, the ability for the organism to grow in foods is critical for 
its ability to cause disease.  One method to control L. monocytogenes’ growth, widely 
used in the ready-to-eat meat industry, is to formulate products with combinations of 
the organic acids lactate and diacetate, as they appear to have synergistic (greater than 
additive) effects.  The purpose of this work was to demonstrate synergistic growth 
inhibition by lactate and diacetate in a statistically rigorous manner.  The approach 
was to grow strains of L. monocytogenes representing the two major genetic lineages 
in broth treated with lactate, diacetate or the combination of both at the same level at 
refrigeration temperature.  The data show the growth inhibitor combination extends 
lag phase and decreases maximum growth rate similarly across both genetic lineages, 
and in a statistically significant manner (a significant interaction between treatments), 
quantitatively proving synergism.  Monte Carlo simulations provided further evidence 
for synergy by predicting significantly slower growth to nominal endpoints, such as a 
1-log increase, for the combination of inhibitors.  This study quantitatively confirms 
the qualitative evidence in the literature for lactate and diacetate synergy and justifies 
the combined use in food product formulations.  The final chapter describes two 
directions to continue this research, specifically (i) using these synergy calculations 
methods to characterize and optimize novel growth inhibiting treatment combinations 
and (ii) using molecular genetics techniques to investigate the mechanisms behind the 
synergistic actions of lactate and diacetate.   
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CHAPTER 1 
THE COMBINATION OF LACTATE AND DIACETATE SYNERGISTICALLY 
REDUCES COLD GROWTH IN BRAIN HEART INFUSION BROTH ACROSS 
LISTERIA MONOCYTOGENES LINEAGES 
Abstract 
Combinations of organic acids are often used in ready-to-eat foods to control 
the growth of Listeria monocytogenes during refrigerated storage.  The purpose of this 
study was to quantitatively assess synergy between two organic acid growth inhibitors 
under conditions similar to those present in cold smoked salmon, and to assess the 
effect of evolutionary lineage on response to those growth inhibitors.  Thirteen strains 
of L. monocytogenes, representing lineages I and II, were grown at 7°C in broth at pH 
6.1 and 4.65% water-phase NaCl which was supplemented with 2% potassium lactate, 
0.14% sodium diacetate, or the combination of both at the same levels.  Our data 
suggest that lineages adapt similarly to these inhibitors, as the only significant growth 
parameter difference between lineages was a minor effect (±0.16 day, p=0.0499) on 
lag phase (λ).   For all strains, lactate significantly extended λ, from 2.6±0.4 to 3.8±0.5 
days (p<0.001), and lowered maximum growth rate (μmax), from 0.54±0.06 to 
0.49±0.04 log10(CFU/mL)/day (p<0.001), compared to the control.  Diacetate was 
ineffective alone, but in combination with lactate, synergistically increased λ to 
6.6±1.6 days (p<0.001) and decreased μmax to 0.34±0.05 log10(CFU/mL)/day 
(p<0.001).  Monte Carlo simulations provided further evidence for synergy between 
diacetate and lactate by predicting signficantly slower growth to nominal endpoints for 
the combination of inhibitors.  This study shows potassium lactate and sodium 
diacetate have significant synergistic effects on both λ and μmax of L. monocytogenes 
at refrigeration temperature in broth and justifies combining these inhibitors, at 
effective levels, in food product formulations.  
2 
Introduction 
Listeria monocytogenes is an opportunistic pathogen that causes human illness 
almost exclusively from foodborne transmission (24, 47).  It possesses heat, acid, and 
osmotic stress response systems, which help it to survive on foods during processing 
as well as during transmission through a human or animal host (41).  Additionally, it is 
psychrotolerant, having the ability to grow at temperatures as low as -0.4°C (51), 
therefore reducing the ability of refrigeration to inhibit L. monocytogenes growth.  The 
species L. monocytogenes can be divided into at least three genetic lineages (53) with 
known differences in virulence (7), gene expression (38), growth, and survival during 
thermal inactivation  (10).  Further, genetic lineages are differentially associated with 
human (lineage I), or environmental and food (lineage II)  prevalence (15). 
L. monocytogenes contamination in ready to eat (RTE) foods is usually at low 
levels (14) and a large infectious dose is typically required to cause human disease 
(46).  Therefore, the ability of L. monocytogenes to multiply in foods is critical for its 
ability to cause disease (8). The organism cannot grow in foods that: are stored frozen, 
have a pH ≤ 4.4, have an aw < 0.92 or that have an effective growth inhibiting measure 
incorporated during production (44).  In situations where growth cannot be prevented 
altogether, strategies that reduce or prevent the ability of L. monocytogenes to grow in 
foods are predicted to significantly reduce listeriosis due to consumption of those 
foods (45). 
Consumption of RTE smoked seafood products has been identified as having a 
high risk per serving for listeriosis (45).  Cold smoked seafood products typically 
contain between 2.5 and 6% water phase salt, have a pH > 5.0, and contain sub-
inhibitory levels of nitrites (100-200 ppm) and phenol compounds (17).  Smoked 
seafood products also have a high prevalence of L. monocytogenes (14), most 
frequently through post-processing contamination at the processing plant, though L. 
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monocytogenes present in raw product can survive the cold smoking process and 
contribute to contamination (17).  The combination of growth-permissive product 
formulations and high rates of contamination create high risk per serving for listeriosis 
because when cold smoked seafood products are contaminated, L. monocytogenes can 
then grow to dangerous levels during refrigerated storage of the product (45, 54).  
In the RTE meat industry, natural and synthetic growth inhibitors (GI) have 
been used to control L. monocytogenes growth, and these methods are beginning to be 
investigated for use in cold smoked seafood products (20).  Often, GI are used in pairs, 
as research has shown that some combinations are more effective together than either 
of the inhibitors used alone (12, 13).  Yet, no standard method exists to evaluate the 
effects of single growth inhibitors or determine synergies when they are used in 
combination.  Previously used methods include: measuring growth of L. 
monocytogenes over time in model systems (37), high throughput screens for single or 
combination treatments that inhibit short-term growth (16, 27), and challenge studies 
measuring growth in actual food products (31, 50, 54).  In studies where synergies 
between GI have been quantitatively demonstrated, they are commonly evaluated by 
showing the effects of a combination of GI are great than the sum of the individual 
effects (31, 37), or by showing that the inhibitors have statistical interaction effects on 
the indicator for growth inhibition (1, 30).   
Combinations of the organic acid GI potassium lactate and sodium diacetate 
are widely used in the RTE meat industry (42), which has resulted in commercial 
production of at least one lactate and diacetate blend (PURASAL OptiForm PD-Plus, 
PURAC America, Inc) that has also been evaluated for use in the cold smoked seafood 
industry (31, 50).  Yet, to the best of our knowledge, the synergistic action of 
potassium lactate and sodium diacetate on L. monocytogenes growth has never been 
demonstrated quantitatively.  The purpose of this study was to evaluate potential 
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synergistic effects of potassium lactate and sodium diacetate on inhibition of L. 
monocytogenes grown at 7°C in broth media adjusted to the water phase NaCl and pH 
of cold smoked salmon, with the aim of demonstrating synergy quantitatively.   
Inhibitors were tested using strains from both lineage I and lineage II to determine if 
there were growth differences between these lineages.  We found that lactate and 
diacetate do synergistically inhibit the growth of L. monocytogenes and the response to 
these GI are similar for the selected strains from the two lineages tested.   
Materials and Methods 
Strain selection. A total of 13 L. monocytogenes isolates (Table 1) were 
selected for growth in Brain Heart Infusion (BHI; Difco, Detroit, MI) broth treated 
with growth inhibitors.  These strains include 7 that belong to lineage I and 6 that 
belong to lineage II.  Among these strains, there is one representative of each of the 10 
unique ribotypes isolated from smoked seafood (15), as well as representatives of 
serotypes commonly involved in foodborne outbreaks (serotypes 4b, 1/2a, and 1/2b).  
Strains of serotype 1/2c as well as strains belonging to lineage III were not included in 
this strain set, as these subtypes are rarely associated with human disease (33, 52). 
Growth Media and Conditions. Growth experiments were designed around a 
two-stage protocol to approximate the transition from pre-growth in a nutrient-limited 
(e.g. food processing) environment to growth in a nutrient-rich (e.g. food product) 
environment treated with GI and held at refrigeration temperature.  The medium for 
the pre-growth was a chemically defined, minimal medium specific to L. 
monocytogenes (2) formulated with 25mM glucose as the carbon source.  Media for 
the experimental growth tests was based on BHI media modified to have 4.65% water 
phase [w.p.] NaCl and pH 6.1, the levels present in commercially processed cold 
smoked salmon (48), and treated with diacetate and/or lactate at levels that would slow 
but not entirely prevent growth over the monitored time.  BHI was modified to make 
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 Table 1. Subtype and source information for Listeria monocytogenes strains used in 
this study. 
Strain Ribotype Lineage Serotype Source Reference 
FSL C1-122 1038B I 4b Human, 
sporadic 
(11, 34) 
FSL F2-693 1042B I 1/2b Human, 
sporadic 
(35) 
FSL R2-154 1042C I 1/2b Smoked 
seafood 
(14, 15) 
FSL R2-182 1043A I 1/2b Smoked 
seafood 
(14, 15) 
FSL J2-064 1052A I 1/2b Bovine (6, 11) 
FSL J1-175 1042A I 1/2b Water _
a 
FSL F6-366 1044A I 4b RTE Meat (29) 
FSL F2-216 1039A II 1/2a Human, 
epidemic 
(15, 36) 
FSL J2-003 1039C II 1/2a Bovine (6) 
FSL F2-032 1045B II 1/2a Smoked 
whitefish 
(35) 
FSL F2-515 1062A II 1/2a RTE meat (35) 
FSL F2-237 1062D II 1/2a Smoked 
salmon 
(35) 
FSL R2-559 1053A II 1/2a RTE meat (29) 
a
-, no data
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this work more relevant to a particular food product, cold smoked salmon, 
though it is not intended as a challenge study, and organic acid levels were not 
intended to entirely prevent growth so that we could fully parameterize the logistic 
bacterial growth model (see „Model Development and Statistical Analysis‟) used for 
analysis of the measured growth data. 
Treatment media were formulated on a water phase basis, by weight, where: % 
water phase [% w.p.] = g dry component / (g dry component + g water).  For example, 
to formulate a solution of BHI with 4.65% w.p. NaCl, first a standard BHI solution 
was made by adding 37 g BHI powder to 1L (1 kg) water noting that BHI contains 5g 
NaCl per 37 g powder, then additional NaCl (43.8 g) was added to the solution so the 
final water phase NaCl (5g + 43.8g / (5g + 43.8g + 1000 g) was 4.65%.  The treatment 
media described below were formulated similarly, adding commercial compounds, by 
weight, to achieve the desired levels while accounting for the relative percentages of 
organic acid, water, and other compounds in each commercial stock.  
The four treatment media (Table 2) were formulated with (i) no added 
inhibitors as control [CTRL], (ii) 0.14% w.p. sodium diacetate  [SDA] (Macco 
Organiques Inc., Valleyfield, Quebec, Canada), (iii) 2% w.p. potassium lactate [PL] 
(PURASAL Hi Pure P-Plus, PURAC America, Inc., Lincolnshire, IL), or (iv) a 
commercial combination of both inhibitors at the same levels (2% PL + 0.14% SDA)  
[PLSDA] (PURASAL OptiForm PD-Plus, PURAC America, Inc.).  We chose to use 
potassium lactate instead of the other commonly available alternative, sodium lactate, 
to be consistent with other recent publications of interest to the smoked fish industry 
that evaluate potassium lactate, e.g. (50), and because recent efforts at sodium 
reduction (26)  in many foods make the potassium salt more attractive than the sodium 
salt. 
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Table 2. Formulations for BHI broth media treated with GI. 
Treatment 
BHI  
(%wp)
a
 
NaCl 
(%wp) 
Diacetate 
(%wp) 
Lactate 
(%wp) 
CTRL 3.70 4.65 -
b 
- 
SDA 3.70 4.65 0.14 - 
PL 3.70 4.65 - 2.00 
PLSDA 3.70 4.65 0.14 2.00 
a 
%wp, percent water phase [g of dry component / (g of dry component + g of water)]. 
b
-, not included. 
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 It is generally believed that organic  acids are biologically active in their 
undissociated form, the concentration of which can be calculated using the Henderson-
Hasselbalch equation: pH = pKa + log([dissociated form]/[undissociated form]) where 
pH is the pH of the solution, [] indicate the molar concentration of either form of the 
organic acid, and the pKas are constants for lactate (3.79) and diacetate (4.79, the pKa 
for acetate, the base anion of diacetate) (21).    Using the Henderson-Hasselbalch 
equation, the percentage of undissociated lactate and acetate in a pH 6.1 solution was 
calculated and multiplied by the concentration (mol total organic acid / kg of solution) 
of lactate and diacetate in the treatment solutions, giving undissociated acid 
concentrations of 0.71 and 0.39 mM/kgtotal for solutions containing lactate and/or 
diacetate, respectively.   For the remainder of this paper we refer to the water phase 
percentages for consistency with recent work evaluating these growth inhibitors in 
food products. 
For growth prior to inoculation in media with growth inhibitors, isolates were 
streaked from frozen stocks of BHI culture maintained at -80°C in 15% glycerol onto 
BHI agar plates, and incubated at 37°C for at least 24 h. Single colonies of each strain 
were inoculated into 5 ml BHI (in 16 mm tubes) which were incubated overnight at 
37°C with constant shaking at 230 rpm; Series 25 Incubator, New Brunswick 
Scientific, Edison, NY).  After 16-20 h, 50 μl of BHI culture were used to inoculate 5 
ml of sterile L. monocytogenes chemically defined medium (2) pre-warmed to, and 
incubated statically at, 16°C.  After growth to log-phase, defined as OD480 = 0.4 
(~24h), 50 μl of culture were transferred to another 5 ml chemically defined medium 
at 16°C and grown to early stationary phase which was reached after 72 h (Figure 1).   
After growth in defined medium, stationary phase cells were used to inoculate 
treatment media at ~2 x 10
3 
CFU/ml.  Treatment media was formulated according to 
Table 2, adjusted to a pH of 6.1 using 6 N HCl and 5 N NaOH, as needed, sterilized 
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Figure 1. Growth of Listeria monocytogenes in defined, minimal medium at 16°C.  
Each point represents the average log(OD480) and standard deviation from 13 strains.  
Readings outside the linear range of the spectrophotometers [log(OD480) ≤1.0] were 
excluded. 
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by autoclaving and then stored at 4°C.  Before each test, fresh media were prepared; 
75 ml for each treatment and strain were aseptically aliquoted into sterile, 300 ml 
Erlenmeyer shake flasks with metal caps (Bellco Glass Co, Vineland, NJ) and chilled 
to 7°C.  Cultures were diluted 1:1,000 in phosphate buffered saline and 75 μl of the 
dilution were used to inoculate each of the treatment flasks filled with 75 ml treatment 
media for a final dilution of 1:10
6
.  Samples of each treatment flask were reserved for 
plating and the flasks were stored, without aeration, at 7°C (the temperature that at 
least 90% of consumer refrigerators are at or below (3)) in a low-temperature 
incubator (VWR Model 2020, West Chester, PA) for the duration of the growth 
period.  To better characterize lag phase, cell density was measured every day from 
day 2 until growth began; subsequently, cell densities were determined every other 
day until cultures reached stationary phase.  For all samples, cultures were serially 
diluted in phosphate buffered saline, 50 μl of the appropriate dilution was plated in 
duplicate on BHI agar using an Autoplate 4000 and colonies were counted with a Q-
Count (Spiral Biotech, Inc., Norwood MA) after incubation at 37°C for at least 24 h. 
Growth for each strain in each treatment was measured in duplicate. 
Growth Model and Statistical Analysis. The four-factor modified logistic 
growth model described by Baranyi and Roberts (5) was used to calculate a lag phase 
(λ), maximum growth rate (μmax) initial cell density (N0) and maximum cell density 
(Nmax) for each strain for each GI treatment.  Regression was carried out using the 
NLStools package (v0.0-5) in R v2.6.2.  Differences between treatments were 
analyzed using a separate fixed effect ANOVA for each parameter.  This design had 4 
factors: lactate, diacetate, evolutionary lineage, and biological replicate, each with two 
levels.  The linear model used for the ANOVA was Y (the growth parameter) = lactate 
| diacetate | lineage + replicate + E (error), where ”|” indicates a full factorial model of 
the grouped parameters.  The relative explanatory contribution of each parameter was 
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quantified by calculating the percentage of the total variation (squared error) in the 
data accounted for by each parameter, i.e. sum squared error for each parameter / total 
sum squared error for the model.  Comparisons of interest, specifically the diacetate-
lactate and diacetate-lactate-lineage interactions, were compared using Tukey‟s 
correction for multiple comparisons.  Additionally, multivariate correlation 
coefficients were calculated to quantify the linear relationship between the regression 
parameters.  Correlations were calculated after (i) grouping the parameters as one data 
set, i.e. calculating the overall correlation in the data including the variability caused 
by growth inhibitor treatment, and (ii) grouping the parameters by growth inhibitor 
treatment, i.e. calculating the correlated nature of parameters within a specific 
treatment separate from the potentially correlated nature of the effects of the 
treatments themselves.  ANOVAs, multiple comparisons and multivariate correlation 
calculations were performed in JMP (v. 7.0, SAS Institute Inc., Cary, NC). 
Monte Carlo simulations. The effect of PL and SDA GI on L. monocytogenes 
growth was studied using Monte Carlo simulation (32) to predict growth to two 
different endpoints based on modified logistic growth model parameters sampled from 
distributions fitted to the experimental growth parameters.  The two endpoints used 
were the time (in days) for 1-log growth from the initial cell density, and the time (in 
days) for growth to 99% of the final cell density.  Simulations were performed using 
the @RISK (v. 4.5, Palisade Corp., Ithaca, NY ) software package integrated into 
Microsoft Excel 2003 (Microsoft Corp., Redmond, WA).   
First, @RISK was used to fit 15 different statistical distributions (BetaGeneral, 
Exponential , ExtremeValue, Inverse Gaussian, Logistic, Log-Logistic, Log Normal, 
Normal, Pareto, Pearson 5 parameter, Pearson 6 Parameter, Triangle, Uniform, and 
Wiebull) to the experimental data (13 strains, 2 reps, n = 26) for each of the 16 unique 
regression parameters (λ, μmax, N0 and Nmax for each of the 4 growth inhibitor 
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treatments), and goodness of fit evaluated with a chi-square test.  The normal 
distribution had the largest p-value averaged over all 16 regression parameter fits, 
therefore was the best fit, and was selected for the Monte Carlo simulations.  Next, 
sampled growth parameters for each treatment were used to predict the times required 
for colony count to increase by 1-log [t where N(t) = N0 + 1 where N(t) and N0 are 
measured in log(CFU per milliliter)] and for colony counts to reach 99% of the final 
density [ t where N(t) = N0 + 0.99(Nmax + N0)].  For each iteration of the Monte Carlo 
simulation, 16 new regression parameters were sampled as correlated, normally 
distributed inputs, where the correlations between parameters for each treatment are 
the calculated correlation coefficients for the experimental data grouped by treatment, 
and the normal distribution is defined by the experimental mean and standard 
deviation for each treatment.   Then, 8 new growth times, one for each treatment and 
endpoint combination, calculated from the sampled parameters were recorded as 
outputs.  The simulation was run for 5000 iterations using Latin Hypercube sampling 
for the input parameters.    Output data were analyzed by median value (50
th
 
percentile), inner quartile range (25
th
 – 75th percentile) and 95% confidence intervals 
for growth time (2.5
th
 - 97.5
th
 percentile) which were found by sorting the results from 
the 5000 iterations by time and reading the appropriate values.   
Results 
Strains from evolutionary lineage I and II respond similarly to GI treatments.  
To determine if the evolutionary lineages of L. monocytogenes responded differently 
to the GI treatments, we compared growth parameters for the four GI treatments 
between the lineages. Growth curves for all 13 strains and four GI treatments (CTRL, 
SDA, PL, and PLSDA) were measured in duplicate, and modified logistic growth 
parameters (λ, μmax, N0 and Nmax) were fit to each individual curve (n = 104).  Of all 
the ANOVA model effects containing lineage (lineage alone and all its crosses), only 
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the main effect of lineage on λ was significant (P = 0.0499).  Overall, lineage II strains 
have a slightly longer average lag time, estimated to be 0.32 day longer than the 
average lag time for lineage I strains.  Although lineage II strains trend towards having 
a longer lag times, lag time differences between evolutionary lineage were not 
significant for a given treatment (Table 3).  All other growth parameters had virtually 
indistinguishable values when the effect of GI treatments was analyzed by lineage.    
Because evolutionary lineage did not have a major effect on growth, all further 
analyses group the data from both lineages together. 
To determine the contribution of strain to variation in growth parameters, an 
additional ANOVA model with a strain predictor nested within lineage was used to 
analyze the growth parameters (full data not shown).  In this analysis, strain had a 
significant (p = 0.006), but small effect on μmax, explaining  5.9% of the total variation 
of the new model.  Strain had a significant (P < 0.001), and greater, effect on No and 
Nmax, explaining 50% and 22% of the variation, respectively.  The variation in N0 due 
to strain reflects the variability in final cell densities in chemically defined media (Fig. 
1) before inoculation into the treatment media. The significant effect of strain on Nmax 
indicates that different strains may grow to slightly different final densities in BHI.  
For both No and Nmax, average differences in cell densities were less than 0.5 
log(CFU/ml).  
PL and PLSDA significantly increase lag phase and reduce maximum growth 
rate. The comparisons between growth inhibitor treatments are summarized in Table 4 
and the individual parameters are available in Table A1.  PL alone significantly (P < 
0.001) extended λ from 2.6 to 3.8 days compared to CTRL (Table 4).  SDA alone had 
no effect on λ (P = 0.79), but when added to PL, significantly (P < 0.001) increased λ 
to 6.6 days, an extension of almost 3 days 
  
 
1
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Table 3. Lineage effects on growth parameters for Listeria monocytogenes at 7°C
a
 
Treatment Lineage λ(days) 
μmax 
[log(CFU/ml)/day] 
N0 
[log(CFU/ml)] 
Nmax 
[log(CFU/ml)] 
CTRL I 2.57 ± 0.37 A
b
 0.54 ± 0.05 AB 3.40 ± 0.10 A 8.56 ± 0.21 BC 
II 2.66 ± 0.43 A 0.54 ± 0.07 A 3.35 ± 0.10 A 8.64 ± 0.22 AB 
SDA I 2.54 ± 0.39 A 0.51 ± 0.03 AB 3.40 ± 0.14 A 8.69 ± 0.16 AB 
II 2.81 ± 0.25 AB 0.52 ± 0.02 AB 3.38 ± 0.13 A 8.81 ± 0.16 A 
PL I 3.73 ± 0.37 BC 0.49 ± 0.04 AB 3.42 ± 0.08 A 8.31 ± 0.16 D 
II 3.92 ± 0.67 C 0.49 ± 0.04 B 3.40 ± 0.07 A 8.33 ± 0.22 CD 
PLSDA I 6.29 ± 1.36 D 0.34 ± 0.04 C 3.43 ± 0.09 A 8.21 ± 0.15 D 
II 7.02 ± 1.72 D 0.33 ± 0.06 C 3.40 ± 0.09 A 8.22 ± 0.29 D 
a
 Results are summarized by mean ± standard deviation for seven lineage I and six lineage II strains tested in duplicate.     
b
 Means within a given column with the same letter are not statistically different from each other (overall α = 0.05, Tukey's 
correction) 
  
 
 Table 4. GI treatments affect growth parameters for Listeria monocytogenes at 7°C
a
 
Treatment 
λ 
(days) 
μmax 
[log(CFU/ml)/day] 
N0 
[log(CFU/ml)] 
Nmax 
[log(CFU/ml)] 
CTRL 2.61 ± 0.39 A
b
 0.54 ± 0.06 A 3.38 ± 0.10 A 8.60 ± 0.21 A 
SDA 2.68 ± 0.35 A 0.52 ± 0.03 AB 3.39 ± 0.13 A 8.75 ± 0.17 B 
PL 3.82 ± 0.53 B 0.49 ± 0.04 B 3.41 ± 0.08 A 8.32 ± 0.18 C 
PLSDA 6.63 ± 1.55 C 0.34 ± 0.05 C 3.41 ± 0.09 A 8.21 ± 0.22 C 
a
 Results are summarized by mean ± standard deviation for 13 strains tested in duplicate (n=26 per treatment).     
b
 Means within a given column with the same letter are not statistically different from each other (overall α=0.05, Tukey's 
correction) 
1
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compared to PL alone.   PL significantly (P < 0.001) lowered μmax compared to the 
control, from 0.54 to 0.49 log(CFU/ml)/day.  The PLSDA treatment further lowered 
(P < 0.001) μmax to 0.34 log(CFU/ml)/day.  Signficant differences in N0 were not 
observed between the 4 treatments. Nmax was signficantly (P < 0.001) lower in both 
treatments containing PL (8.32 log(CFU/ml) for PL and 8.21 log(CFU/ml) for 
PLSDA) compared to the other treatments (8.60 log(CFU/ml) for CTRL and 8.75 
log(CFU/ml) for SDA), though the difference of less than 0.5 log(CFU/ml) may not be 
biologically relevant.   
Further, the growth parameters λ, μmax and Nmax were significantly (P < 0.001, 
by pairwise comparison) correlated in the full data set, as suggested by the means in 
Table 4,  with λ inversely correlated to μmax (Pearson‟s correlation coefficient was -
0.88) and Nmax (-0.72) and μmax directly correlated to Nmax (0.70).  The trends in the 
correlations between parameters grouped by growth inhibitor treatment were similar 
(e.g. -0.48, -0.53, and 0.78 for λ to μmax, λ to Nmax, and μmax to Nmax in the CTRL 
treatment), though generally the correlations were weaker and often non-significant 
(Table A2).   
Synergistic effects of PL and SDA on λ and µmax.  Beyond the comparisons 
of treatment means, ANOVA showed a significant interaction between diacetate and 
lactate for λ (P < 0.0001), μmax (P < 0.0001) and Nmax (P = 0.002) (Table 5), indicating 
that these GI act synergistically in this system.  The synergistic effect of PL and SDA 
on λ is evident, as SDA alone was ineffective at increasing λ, yet the combination of 
PLSDA led to an average 2.5 times longer λ compared to CTRL (Figure 2A).  The 
combination of PLSDA led to an average 1.6 times slower μmax compared to CTRL, 
while SDA alone and PL alone had minimal effects on μmax (Figure 2B).   Whether 
  
Table 5. Summary of ANOVA for effects of GI treatments and lineage on growth parameters.  
  Type III ANOVA P values for:  Percent of total squared error for
a
: 
Model Effect λ μmax N0 Nmax  λ μmax N0 Nmax 
ANOVA overall <0.001
b
 <0.001 0.572 <0.001  NA NA NA NA 
SDA <0.001 <0.001 0.706 0.555  15.43 22.78 0.14 0.10 
PL <0.001 <0.001 0.155 <0.001  49.50 41.20 2.02 31.83 
SDA X PL <0.001 <0.001 0.853 0.002  14.12 12.85 0.03 3.02 
Lineage 0.0499 0.885 0.140 0.132  0.78 0.00 2.17 0.66 
SDA X lineage 0.258 0.947 0.771 0.796  0.25 0.00 0.08 0.02 
PL X lineage 0.425 0.435 0.901 0.281  0.13 0.14 0.02 0.34 
SDA X PL X lineage 0.622 0.908 0.783 0.740  0.05 0.00 0.07 0.03 
Replicate 0.022 0.011 0.147 0.279  1.06 1.52 2.10 0.34 
Error NA NA NA NA  18.68 21.51 93.35 63.65 
a 
SSEeffect / SSEtotal  X 100. 
b
 Significant (P < 0.05) effects are in italics.
1
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Figure 2. Changes in λ (A) and μmax (B) are dependent on the presence or absence of 
PL and SDA in the growth medium.  □, with PL treatment, ▲, without PL treatment.  
Points are means of growth parameters for each inhibitor treatment with error bars of 1 
standard deviation (n = 26 per treatment).  The control treatment is marked with an 
asterisk. 
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statistical interaction implies synergy for Nmax is unclear because of the conflicting 
action of SDA.  Alone, SDA significantly (P < 0.01), though only slightly, increases 
Nmax compared to CTRL, but when used in combination with PL the action is reversed, 
with a non-significant (P = 0.064) reduction in Nmax for PLSDA as compared with PL.   
PL, SDA and PLSDA have the largest effect on variance of growth parameters. 
The relative contributions of each predictor to the overall variation in the experimental 
data was calculated (Table 5) was percentage of total squared error.  For λ and μmax the 
largest source of variation  was PL, with 49 and 41% of the total for λ and μmax, 
respectively.  This indicates that the main contribution to variation in λ and μmax was 
due to the presence or absence of lactate in the growth medium.  The contributions of 
SDA and the PL-SDA interaction to variance in λ and μmax was half or less than the 
effect of PL, respectively 15 and 14% for λ and 23 and 13% for μmax.  These relative 
percentages for λ and μmax were similar to the unexplained variation in the data, 
represented by the error with 19 and 22%, respectively. Biological variation also had a 
significant, though minor, effect for these parameters, indicated by the small 
contribution of the “replicate” predictor to the variation (1.1 and 1.5% for λ and μmax, 
respectively).  For Nmax, only  error, PL and the SDA-PL interaction had significant 
explanatory power, corresponding to 64, 32 and 3.0% of the variance.   
Treatment with the combination of lactate and diacetate slows L. 
monocytogenes growth to nominal endpoints. Monte Carlo simulations were used to 
predict the effect of GI on the time it takes for L. monocytogenes to increase colony 
counts (i) by 1 log and (ii) to within 99% of its maximum density.  Of the 15 
distributions tested, only 3-logistic, normal and triangle- were successfully fitted to all 
16 unique growth parameters.  Average P values to reject the chi-square test for 
goodness of fit were 0.636, 0.638 and 0.618 for the logistic, normal and triangle 
distributions, respectively.  All 16 unique growth parameters (λ, μmax, N0, and Nmax for 
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each GI treatment) were therefore modeled with normal distributions for the Monte 
Carlo simulations, using the experimental average and standard deviation values 
shown in Table 4 and the calculated correlations for the regression parameters grouped 
by treatment (Table A2).   
Results from the Monte Carlo simulations for the time for colony counts to 
increase by 1log and to 99% of maximum density suggest that while individual GI 
might not be effective in extending the time to reach these endpoints, the combination 
treatment may be effective.  The estimated times for growth to each endpoint do not 
significantly differ for single growth inhibitor treatments compared to CTRL (Figure 
3) and the median times showed only very slight increases, 5.79 and 15.7 days for PL 
and 4.52 and 14.7 days for SDA compared to 4.40 and 14.0 days for CTRL, for times 
to increase by 1 log and to 99% of final density, respectively. Conversely, the PLSDA 
treatment was predicted to significantly (95% confidence) increase the time required 
for colony counts to increase to 99% of final density compared to CTRL and both 
SDA and PL inhibitor treatments, to a median 23.8 days (95% confidence interval of 
19.0 to 30.4 days), a >50% increase in median time.  Similarly, PLSDA treatment was 
predicted to significantly increase the time required for colony counts to increase by 
1log compared to CTRL and SDA treatment, to a median of 9.52 days (95% 
confidence interval of 6.31 to 12.8 days), also a >50% increase in median time.  
Although the median predicted time for colony counts to increase by 1 log increased 
by over 50% for the PLSDA treatment compared to PL, the 95% confidence intervals 
for each treatment overlap.  The greater uncertainty in the PLSDA predictions may be 
partially attributed to the increased variability in the observed lag times for that 
treatment, evidenced by standard deviation of λ at least threefold greater than in the 
other treatments (Table 4) 
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Figure 3.  Diacetate and lactate synergistically extend the time predicted by Monte 
Carlo simulations required for Listeria monocytogenes outgrowth.  (A) Time required 
for colony counts to increase by 1 log from predicted N0 (N1 log = N0 + 1). (B) Time 
required for colony counts to reach 99% of the difference between Nmax and N0 [N99% = 
N0 + 0.99 (Nmax - N0)].  Median line is the 50
th
 quantile, box is drawn at the 25
th
 and 
75
th
 quantile, and the whiskers are drawn at the 97.5
th
 and 2.5
th
 quantile from 5,000 
iterations.   
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Discussion 
This study investigated the effects of sodium diacetate, potassium lactate, and 
their combination on the growth of strains representing two evolutionary lineages of L. 
monocytogenes at 7°C in broth media adjusted to the water phase salt and pH of cold 
smoked salmon.  L. monocytogenes  counts over time were used to generate modified 
logistic model parameters characterizing λ, μmax, N0, and Nmax.   Statistical analysis of 
these growth parameters showed that PL and SDA synergistically interact to extend λ 
and lower μmax, while Nmax was slightly reduced by lactate treatment.  Monte Carlo 
simulations further suggest synergy between diacetate and lactate on slowing growth 
to nominal endpoints (i.e. time for colony counts to increase by 1-log and to 99% of 
maximum density). 
The effect of SDA and PL treatments can be separated into effects on 
individual growth parameters. By evaluating changes in growth rate parameters, these 
two growth inhibitors were shown to affect three distinct elements of a bacterial 
growth curve, each of which can be independently analyzed and used to assess growth 
inhibitor efficacy.  Decomposition of the elements of a growth curve has been used to 
evaluate the effect of other hurdles, e.g. PLSDA, growth temperature, and freezing 
stress (54) or PLSDA, growth temperature, and pH (1), on the lag time and specific 
growth rate of L. monocytogenes.   
After fitting logistic model parameters to experimental growth curves from 
CTRL, SDA, PL and PLSDA treatments, our statistical analysis of the parameters 
showed that SDA and PL caused different effects on bacterial growth.  Lactate alone 
increased λ, from 2.6 to 3.8 days, and lowered μmax, from 0.54 to 0.49 
log(CFU/ml)/day, whereas SDA alone showed no significant effect on either 
parameter.  In the combined treatment, PLSDA, both λ and μmax were further lowered 
compared to PL alone.   Studies that have evaluated the effects of a range of PL and 
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SDA levels on lag phase and specific growth rate in broth at different temperatures 
and pH (1), on the predicated growth-no growth boundary in various cold-smoked 
seafood products (25), and on storage temperature (54), suggest that the levels of GI 
used in our study, 2.0% potassium lactate and 0.14% sodium diacetate, fall at a 
transition between slowing and fully inhibiting growth.  Of particular relevance, Vogel 
et al. (50) used levels of PL (2.0% w.p.) and SDA (0.14% w.p.) identical to those used 
here, and reported moderately slower growth of L. monocytogenes in cold smoked 
salmon juice at 10°C as compared to our findings (in modified BHI broth) that 
individual inhibitors have minimal effect.  In contrast to our results, which showed 
very limited effects of the GI treatments on Nmax, Vogel et al. found the combination 
of the two inhibitors completely prevented growth for 28 days in salmon juice and 
minced cold-smoked salmon at 10°C.  At these transition levels, differences in the 
complex nature of broth and food systems may influence the growth boundary, e.g. 
chemical changes in salmon during smoking such as the incorporation of phenolic 
compounds, may add additional hurdles to growth that lead to the differences between 
our results and those in Vogel et al (50).  Hence, our data do not indicate that 
combination treatments cannot be used to formulate RTE products that do not allow 
for growth, but rather suggest that GI combinations need to be optimized for specific 
food matrices. 
Nmax was affected by PL, where treatments containing  potassium lactate had a 
reduced Nmax, although only by ~0.5 log(CFU/ml).  Other studies have shown 
inconsistent effects of PL and SDA on Nmax, likely due to differences in temperature 
and food matrix. One study showed a slightly lower (~0.5 log) maximum density 
following lactate treatment in refrigerated bologna (41); another found that maximum 
population density decreased from 8.5 to 7.1 log(CFU/g) at 9.1°C following increasing 
PLSDA treatments but not higher storage temperatures (19); and a different study 
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showed that growth in brine injected, minced, cold smoked salmon treated with 
combinations of PLSDA showed no difference in final density over 28 day at 10°C, 
but over ~40 days at 10°C growth on cold smoked salmon injected with 2.1% PL and 
0.12% SDA stopped after ~2-log increase (50).   These studies suggest PL may cause 
a slight reduction in maximum cell density in some food systems, though further work 
is needed to conclusively demonstrate such an effect. 
 SDA and PL synergistically extend lag phase and reduce maximum growth 
rate.   Our data show that PL and SDA interact in a statistically significant manner to 
increase λ and reduce μmax, indicating a synergistic action of these growth inhibitors 
when used in combination (39).  The synergistic effects of lactate and diacetate are 
consistent with other studies that were not necessarily designed to test this 
relationship.  For example, Neetoo et al. (28) found, during growth at 35°C in tryptic 
soy agar with 0.6% yeast extract, that while sodium lactate and SDA did not prevent 
growth at half their MICs (2.8 and 0.11% [wt/wt], respectively), the combination did 
prevent growth.  Additionally, sodium lactate at 2.4 or 4.8% and SDA at 0.125% 
allowed growth, the binary combinations (sodium lactate 2.4 or 4.8% with SDA 
0.25%) prevented growth.   
One potential application of the demonstrated synergy is to develop predicative 
secondary models that incorporate interactions between GI for more accurate 
prediction of growth responses.  Various model have been proposed including (i) a 
response surface modeling lag phase duration and growth rate of L. monocytogenes as 
a function of temperature, lactate concentration and diacetate concentration where the 
synergy was explicitly quantified by a parameter scaling the lactate X diacetate 
interaction term (19) (ii)a model for the maximum growth rate of L. monocytogenes 
incorporating many environmental parameters that included an interactions effect term 
where the individual effects of lactate and diacetate were multiplied (25), and 
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predicted the growth-no growth boundary of L. monocytogenes having a non-linear, 
concave up, relationship between lactate and diacetate levels; and (iii) a multiplicative 
model for growth rate based on fractions of cardinal growth parameters  that 
incorporates interactions between environmental parameters and inhibitory 
compounds (4), which assumes multiplicity of individual inhibitory effects.  Contrary 
to these claims to model interactions, Lambert and Bidlas (22) argue that apparent 
interactions between combined growth inhibitors are actually the result of independent 
inhibitor effects, e.g., modeling interactions with multiplicative terms but not 
additional empirical parameters (as in (4)) indicates a more complex independent 
effect, not interactions.  Regardless of the specific details, accurate modeling of the 
synergistic effects of growth inhibitor combinations is a critical step in optimizing 
treatment levels for food products.     
Strains from two evolutionary lineages respond similarly to growth inhibitor 
treatment when grown at 7°C in broth. Our data has shown that strains representing L. 
monocytogenes lineage I or II do not have significantly different mean values for any 
of the four growth parameters during growth in media treated with organic acid GI, 
although ANOVA analysis did show lineage II had slightly longer lag times overall.  
Vogel et al. (50) found that two strains of different lineages and serotypes (lineage I 
serotype 4, lineage II serotype 1/2 (49)) isolated from smoked seafood processors had 
similar growth curves in minced cold smoked salmon treated with the same 
combination of lactate and diacetate (2% PL and 0.14% SDA).   In contrast, De Jesus 
and Whiting (10) found that strains representing lineage II had significantly shorter 
mean lag-time durations than strains representing either lineage I or III when grown at 
5°C in BHI at pH 6.5 with 0.1 M lactate and Lianou et al. (23) found that one lineage 
II strain had a higher maximum growth rate in tryptic soy broth with 0.6% yeast 
extract at 4°C than three other lineage I strains and one lineage III strain.  The 
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ambiguity in the literature suggests that the effect of genetic lineage on growth at low 
temperatures in the presence of organic acids may be minor and further studies will 
need to be designed to specifically isolate lineage effects from confounding factors 
such as serotype or source.    
The minimal effect of lineage on low-temperature growth observed here 
contrasts with research that has shown virulence, metabolic, and ecological differences 
between lineages.  Lineage I strains have a predicted infectious dose about 5 orders of 
magnitude higher than lineage II strains (7).  Lineage I isolates are overrepresented 
among human clinical isolates, while lineage II isolates are overrepresented among 
environmental and food isolates (15).  It seems that although evolutionary lineage does 
affect some aspects of L. monocytogenes physiology, those differences may not be 
highly relevant to the ability to overcome organic acid GI stresses at low temperature 
under the conditions used here.   
Monte Carlo simulations may be useful predictors of GI treatment efficacy.  
The preceding analyses of the effect of GI on growth parameters are useful analytical 
tools but do not directly address the fundamental question of whether or not GI, alone 
or in combination, lead to a reduction in L. monocytogenes levels at the time of 
consumption, therefore reducing the risk of human listeriosis.  Such a question is 
better addressed by risk assessments that use both scientific knowledge and 
uncertainty to come to a conclusion (45).   Risk assessments are useful because they 
quantify the uncertainty in growth responses based on data from many strains and 
avoid extrapolating from growth data based on a few, or even a single, strain.  Given 
that members of the scientific community (18, 46), as well as some U.S. (44) and EU 
(9) regulatory agencies, are considering the principle that RTE foods contain less than 
100 CFU/g of L. monocytogenes at the end of their shelf life are acceptable for human 
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consumption, accurate assessment of growth throughout a product‟s shelf life will 
become essential to product safety.   
We used our experimentally measured growth parameters as the input for 
Monte Carlo simulations to probe two questions, the time required for L. 
monocytogenes to increase in colony count (i) by 1 log(CFU/ml) and, (ii) to 99% of its 
maximum density, based on the distribution of growth parameters measured 
experimentally.  Although statistical analysis of growth parameters showed that 
individually PL would have significant effects on λ and μmax, the Monte Carlo 
simulations show more uncertainty, and do not support the conclusion that individual 
GI, at the levels used in this study, would have any effect on outgrowth times in broth.  
Yet, the 95% confidence intervals of the PLSDA simulations do show that the 
combined treatment of BHI broth with 0.14% SDA and 2% PL will extend the time 
required for growth to both endpoints compared to the control.  These results imply 
that although the individual growth inhibitors tested here are not strong enough to 
slow growth alone, the synergies proven in deconstructive analyses do create strong 
enough inhibition that the combination treatment would effectively slow growth of L. 
monocytogenes in broth to increases of 1-log colony counts and to within 99% of the 
final density.  In the future, this approach, along with optimization of GI levels for 
specific foods, could be used to help predict acceptable shelf life, taking in 
consideration appropriate public health goals, such as Healthy People 2010 (43).   
In conclusion, by proving statistical interaction between GI treatments on 
growth parameters, we found that PL and SDA act synergistically to extend the lag 
phase and reduce the maximum growth rate of L. monocytogenes grown in BHI broth 
media at 7°C, modified for physiological relevance to cold smoked salmon (4.65% 
w.p. salt at pH 6.1).  Specifically, 2.0% w.p.PL alone increased lag time and reduced 
the maximum growth rate, and further growth inhibition was gained by adding 0.14% 
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SDA.  Monte Carlo simulations based on these data predict that while both PL and 
SDA used at levels tested here are ineffective at reducing growth of L. monocytogenes, 
their use in combination will significantly extend the time needed for this pathogen to 
grow to potentially dangerous levels in broth media at refrigeration temperature.  
Future challenge studies in real food products can utilize the synergistic action of 
potassium lactate and sodium diacetate to develop efficient, growth inhibiting, product 
formulations at minimal cost to processors. 
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CHAPTER 2 
 DIRECTIONS FOR FUTURE RESEARCH  
This research developed a statistical methodology to prove synergistic action 
of growth inhibitors by decomposing the effects of growth inhibiting treatments into 
effects on individual growth parameters and then testing for statistically significant 
interactions between inhibiting treatments.  As this work tested only one level of each 
treatment using only phenotypic measures (growth curves), neither dose dependant 
variations in synergistic effect, nor the mechanisms of the observed synergy could be 
elucidated.  Therefore, future research could focus on:  
Synergy Optimization and Screening 
One reason that processors are interested in formulating products with 
synergistic growth inhibitors is that they suggest a method to achieve greater growth 
inhibition at less cost (economic, organoleptic, etc.) than with individual inhibitor 
formulations.  While the data presented in this thesis prove the synergy is real, they do 
not answer the industrial relevant questions of which combination levels provide the 
maximum synergy benefit, or which combination of levels would provide effective 
growth inhibition at the least cost.  These questions could be addressed by using 
response surface models, e.g. [11], to test multiple levels of inhibitors and determine 
(simplest) where the combination where maximum synergy occurs or (more relevant) 
the inhibitor combination function that maximizes synergy for all levels of overall 
growth inhibition.  As response surface methods require the testing of many different 
treatment levels, the result from this work that that lag phase and maximum growth 
rate are highly correlated justify using single endpoint growth measures, such as time-
to-detection [9], that are cheaply measured using automated plate readers to lower the 
time and cost of designed experiments.  Such high-throughput growth methods can 
also be used to screen novel growth inhibitors, as in [6], although experiments should 
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be performed at industrially relevant cold temperatures and with Analysis of Variance, 
as opposed to other classification methods, to prove synergies between combinations. 
Mechanisms of Synergistic Growth Inhibition 
The classic theory of how organic acids inhibit growth of bacteria and yeasts -  
the undissociated acid in solution diffuses across the cell membrane, dissociates into 
non-diffusible hydrogen cations and acid anions, and accumulation of intracellular 
ions is thought to have many growth inhibiting effects including reduction of the 
proton motive force, reduction of intracellular pH, interference with microbial 
metabolism, and anion toxicity [4, 5, 8] – cannot explain why some organic acids, 
such as lactate and diacetate, show synergistic effects, as opposed to additive effects 
stemming from similar mechanisms of action.  While a few studies [1-3, 7] have 
begun to define the transcriptomic bacterial response to single organic acid stresses, or 
the proteomic response to the combination of two organic acids [10], these studies are 
all designed to determine the response to single treatments, not combinations.  To 
accurately study the mechanism of synergy between two inhibitors, studies should be 
designed to gather transcriptomic or proteomic data analogous to this phenotypic data, 
e.g. microarray hybridization between control, lactate, diacetate, and combination 
treatments, and tested for statistically significant interactions in gene or protein 
expression.  Mapping these results to physiological pathways may indicate where 
these organic acids have emergent synergistic properties and suggest targets for the 
rational design of novel growth inhibiting combination treatments.   
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APPENDIX 
Table A1. Growth parameters for each strain grown in BHI broth at 7°C in the 
presence or absence of sodium diacetate and/or potassium lactate. 
Treat-
ment
a
 Strain 
Lin-
eage 
λ 
[days] 
umax 
[log(CFU/ml)/day] 
N0 
[log(CFU/ml]) 
Nmax 
[log(CFU/ml)] 
rep1 rep2 rep1 rep2 rep1 rep2 rep1 rep2 
CTRL c1-122 1 2.8 3.3 0.58 0.53 3.4 3.5 8.7 8.5 
CTRL f2-693 1 2.7 2.2 0.47 0.58 3.4 3.5 8.3 8.7 
CTRL f6-366 1 2.2 2.1 0.56 0.60 3.4 3.5 8.8 8.9 
CTRL j1-175 1 2.7 2.4 0.49 0.60 3.5 3.4 8.4 8.7 
CTRL j2-064 1 2.6 2.5 0.51 0.51 3.4 3.4 8.6 8.5 
CTRL r2-154 1 3.2 2.2 0.47 0.58 3.3 3.2 8.2 8.4 
CTRL r2-182 1 2.4 2.4 0.53 0.49 3.2 3.4 8.7 8.4 
CTRL f2-032 2 2.7 2.4 0.50 0.48 3.3 3.2 8.6 8.3 
CTRL f2-216 2 3.1 3.4 0.58 0.52 3.4 3.4 8.6 8.4 
CTRL f2-237 2 2.3 3.0 0.49 0.50 3.2 3.6 8.6 8.6 
CTRL f2-515 2 3.0 2.1 0.47 0.60 3.3 3.4 8.7 8.8 
CTRL j2-003 2 3.1 2.2 0.51 0.62 3.3 3.3 8.5 8.9 
CTRL r2-559 2 2.5 2.3 0.58 0.69 3.4 3.4 8.9 9.0 
SDA c1-122 1 2.8 2.6 0.55 0.54 3.5 3.5 8.8 8.7 
SDA f2-693 1 2.4 2.3 0.53 0.46 3.4 3.6 8.7 8.6 
SDA f6-366 1 3.5 2.8 0.48 0.49 3.5 3.5 8.6 8.8 
SDA j1-175 1 2.3 2.6 0.53 0.53 3.2 3.5 8.9 8.6 
SDA j2-064 1 2.4 2.3 0.53 0.47 3.5 3.3 8.8 8.4 
SDA r2-154 1 2.0 2.9 0.50 0.52 3.2 3.2 8.5 8.6 
SDA r2-182 1 2.3 3.0 0.55 0.51 3.2 3.3 8.9 8.6 
SDA f2-032 2 2.8 3.0 0.55 0.53 3.3 3.5 8.9 8.5 
SDA f2-216 2 2.8 3.1 0.55 0.51 3.4 3.0 8.9 8.7 
SDA f2-237 2 2.5 2.5 0.55 0.52 3.3 3.4 8.9 8.8 
SDA f2-515 2 2.5 2.7 0.54 0.49 3.4 3.4 9.0 8.8 
SDA j2-003 2 2.7 3.1 0.54 0.52 3.4 3.6 9.0 8.8 
SDA r2-559 2 3.2 4.0 0.49 0.51 3.4 3.5 8.9 8.3 
PL c1-122 1 2.6 3.2 0.54 0.53 3.5 3.5 8.7 8.5 
PL f2-693 1 2.3 3.1 0.46 0.57 3.6 3.5 8.6 8.5 
PL f6-366 1 2.8 3.7 0.49 0.54 3.5 3.5 8.8 8.4 
PL j1-175 1 2.6 4.0 0.53 0.54 3.5 3.4 8.6 8.2 
PL j2-064 1 2.3 3.5 0.47 0.50 3.3 3.3 8.4 8.2 
PL r2-154 1 2.9 3.5 0.52 0.47 3.2 3.5 8.6 8.1 
PL r2-182 1 3.0 3.8 0.51 0.44 3.3 3.3 8.6 7.9 
PL f2-032 2 3.0 4.6 0.53 0.51 3.5 3.5 8.5 8.0 
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Table A1. (Continued) 
PL f2-216 2 3.1 4.2 0.51 0.48 3.0 3.4 8.7 8.5 
PL f2-237 2 2.5 3.3 0.52 0.51 3.4 3.4 8.8 8.4 
PL f2-515 2 2.7 2.7 0.49 0.50 3.4 3.4 8.8 8.6 
PL j2-003 2 3.1 3.3 0.52 0.57 3.6 3.5 8.8 8.6 
PL r2-559 2 2.8 6.3 0.52 0.36 3.5 3.5 9.0 8.2 
PLSDA c1-122 1 6.3 6.4 0.36 0.30 3.5 3.5 8.2 8.2 
PLSDA f2-693 1 7.6 4.5 0.29 0.38 3.4 3.4 7.9 8.3 
PLSDA f6-366 1 5.0 5.8 0.37 0.37 3.5 3.5 8.6 8.3 
PLSDA j1-175 1 7.9 4.8 0.33 0.40 3.4 3.4 8.1 8.3 
PLSDA j2-064 1 6.7 6.1 0.35 0.30 3.6 3.4 8.2 8.1 
PLSDA r2-154 1 9.3 4.5 0.31 0.33 3.3 3.2 8.0 8.3 
PLSDA r2-182 1 6.5 6.7 0.34 0.29 3.3 3.4 8.1 8.2 
PLSDA f2-032 2 7.4 10.2 0.26 0.27 3.3 3.4 7.9 7.5 
PLSDA f2-216 2 7.5 7.8 0.39 0.31 3.6 3.4 8.2 8.1 
PLSDA f2-237 2 7.3 8.4 0.30 0.31 3.5 3.4 8.4 8.2 
PLSDA f2-515 2 8.3 4.0 0.29 0.43 3.4 3.3 8.2 8.4 
PLSDA j2-003 2 7.2 5.2 0.27 0.39 3.2 3.3 8.2 8.5 
PLSDA r2-559 2 5.4 5.5 0.39 0.39 3.5 3.5 8.6 8.4 
a
CTRL, control; SDA, sodium diacetate; PL, potassium lactate; PLSDA, combination 
of sodium diacetate and potassium lactate.
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Table A2. Correlation coefficients between regression parameters for the entire data 
set (overall correlation) and for the parameters grouped by growth inhibitor treatment 
(CTRL, SDA, PL, and PLSDA correlations). 
 Parameter  λa  μmax
a
  N0
a
  Nmax
a
  
Overall correlation, n=104  
λ  1.00  -0.879  0.128  -0.718  
μmax  -0.88  1.000  -0.023  0.705  
N0  0.13  -0.023  1.000  -0.015  
Nmax  -0.72  0.705  -0.015  1.000  
CTRL treatment correlation, n=26  
λ  1.000  -0.477  0.234  -0.534  
μmax  -0.477  1.000  0.144  0.781  
N0  0.234  0.144  1.000  0.126  
Nmax  -0.534  0.781  0.126  1.000  
SDA treatment correlation, n=26  
λ  1.000  -0.111  0.157  0.009  
μmax  -0.111  1.000  -0.127  0.560  
N0  0.157  -0.127  1.000  0.031  
Nmax  0.009  0.560  0.031  1.000  
PL treatment correlation, n=26  
λ  1.000  -0.386  0.051  -0.556  
μmax  -0.386  1.000  0.387  0.302  
N0  0.051  0.387  1.000  0.182  
Nmax  -0.556  0.302  0.182  1.000  
PLSDA specific correlation, n=26  
λ  1.000  -0.732  -0.024  -0.714  
μmax  -0.732  1.000  0.340  0.650  
N0  -0.024  0.340  1.000  0.201  
Nmax  -0.714  0.650  0.201  1.000  
a
 significant effects (p<0.05) are italicized  
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Table A3. Strains that were discovered to grow slower than average in DM2 during 
the course of this project.  Growth data from the experiments supporting these 
conclusions follow in Figures A1 to A5. Lineage, serotype, and ribotype data come 
from pathogen tracker.   
FSL 
designation Lineage Serotype Ribotype Source 
Supporting 
Figure A# 
Strains that failed to reach OD480 > 1.0 in DM2   
FSL N3-013 LI 4b 1042B pate outbreak 3 
FSL R2-585 LI 4b 1042B food epidemic 4 
FSL N1-017 LI 4b 1042C trout in brine 1 
FSL R2-435 LI 
 
1042C smoked seafood 2 
FSL J1-167 LI 1/2b 1042B human, sporadic 2 
Strain that grew slowly in DM2 but did eventually reach OD480 > 1.0   
FSL J1-194 LI 1/2b
a 
1042B human, sporadic 1,3,5 
FSL R2-503 LI 1/2b 1051B gastroenteritis outbreak, 1994 3,5 
FSL R2-597 LI 1/2b 1051B epidemic RTE Food (Dairy) 4,5 
FSL J1-116 LI 4b 1042B human epidemic 4,5 
FSL J1-126 LI 4b 1038B human epidemic 4,5 
FSL R2-502 LI 1/2b 1051B food, chocolate milk 4,5 
FSL R2-598 LI 1/2b 1051B human epidemic 4,5 
a
 Serogroup designation from multiplex PCR. 
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Figure A1. Growth of 13 strains in DM2 on 3-3-2008 in preparation for the paper in 
this thesis.  
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Figure A2.  Growth of a revised set of 13 in DM2 on 3-10-2008 in preparation for the 
paper in this thesis.  
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Figure A3.  Growth of 20 strains (not all shown) in DM2 on 7-12-09 in preparation 
for work on a New York Sea Grant project.  
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Figure A4.  Growth of 7 strains in DM2 on 7-16-2009 to in preparation for a work on 
a New York Sea Grant project.  
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Figure A5.  Re-test of the growth of the strains in Figure A4 in DM2 on 9-14-2009. 
